Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
US2016200867A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016200867-A1 |
| Application number | US-201615075750-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 21, 2016 |
| Priority date | Nov 18, 2009 |
| Publication date | Jul 14, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.
Opening claim text (preview).
1 - 50 . (canceled) 51 . A method comprising the step of alkoxylating in a suitable solvent a previously isolated alkoxylatable oligomer to form an alkoxylated polymeric material, wherein the previously isolated alkoxylatable oligomer has a known and defined weight-average molecular weight of greater than 300 Daltons. 52 . The method of claim 51 , wherein the previously isolated alkoxylatable oligomer has a known and defined weight-average molecular weight of greater than 500 Daltons. 53 . The method of claim 51 , wherein both the previously isolated alkoxylatable oligomer and the alkoxylated polymeric product are soluble in the suitable solvent. 54 . The method of claim 51 , wherein the previously isolated alkoxylatable oligomer is prepared by (a) alkoxylating a precursor molecule having a molecular weight of less than 300 Daltons to form a reaction mixture comprising an alkoxylatable oligomer, and (b) isolating the alkoxylatable oligomer from the reaction mixture. 55 . The method of claim 51 where the alkoxylation utilizes ethylene oxide as an alkoxylation agent. 56 . The method of claim 54 , wherein the precursor molecule is selected from the group consisting of glycerol, diglycerol, triglycerol, hexaglycerol, mannitol, sorbitol, pentaerythritol, dipentaerthitol, and tripentaerythritol. 57 . The method of claim 51 , wherein both the previously isolated alkoxylatable oligomer and the alkoxylated polymeric product each has from one to eight primary hydroxyl groups. 58 . The method of claim 57 , wherein each of the one to eight primary hydroxyl groups is the result of an alkoxylation reaction. 59 . The method of claim 57 , wherein the neither the previously isolated alkoxylatable oligomer and the alkoxylated polymeric product has a hydroxyl group of the precursor molecule. 60 . The method of claim 51 , wherein both the previously isolated alkoxylatable oligomer and the alkoxylated polymeric product each has a branched structure. 61 . The method of claim 60 , wherein the branched structure is a 4- to 8-arm branched structure. 62 . The method of claim 61 , wherein the branched structure is a 4-arm branched structure. 63 . The method of claim 61 , wherein the branched structure is a 5-arm branched structure. 64 . The method of claim 61 , wherein the branched structure is a 6-arm branched structure. 65 . The method of claim 61 , wherein the branched structure is an 8-arm branched structure. 66 . The method of claim 51 , wherein the previously isolated alkoxylatable oligomer has the following structure: wherein the average value of n within the structure is from 2 to 50. 67 . The method of claim 51 , wherein the alkoxylated polymeric material has the following structure: wherein the average value of all the instances of n within the structure is from 10 to 1000. 68 . The method of claim 51 , wherein the previously isolated alkoxylatable oligomer has the following structure: wherein the average value of all instances of the value of n within the structure is from 2 to 35. 69 . The method of claim 51 , wherein the alkoxylated polymeric material has the following structure: wherein the average value of all instances of the value of n within the structure is from 10 to 750. 70 . The method of claim 51 , wherein the previously isolated alkoxylatable oligomer has the following structure: wherein the average value of all instances of the value of n within the structure is 2 to 35. 71 . The method of claim 51 , wherein the alkoxylated polymeric material has the following structure: wherein the average value of all instances of the value of n within the structure is 10 to 600. 72 . The method claim 67 , wherein the average value of all instances of the value of n within the structure is from 50 to 400. 73 . The method claim 67 , wherein the average value of all instances of the value of n within the structure is from 50 to 300. 74 . The method of claim 66 , wherein all values of n are within three standard deviations of each other. 75 . The method of claim 66 , wherein all values of n are within two standard deviations of each other. 76 . The method claim 66 , wherein all values of n are within one standard deviation of each other. 77 . The method of claim 51 , wherein the suitable solvent include organic solvents selected from the group consisting of tetrahydrofuran (THF), dimethylformamide (DMF), toluene, benzene, xylenes, mesitylene, tetrachloroethylene, anisole, and mixtures of the foregoing. 78 . The method of claim 51 , wherein the suitable solvent is selected from the group consisting of toluene, xylene, mesitylene, tetrahydrofuran (THF), and mixtures of foregoing. 79 . The method of claim 51 , wherein the suitable solvent is toluene used in quantities that after ethoxylation the solvent consists more than 25 wt % and less than 75 wt % of the reaction mixture. 80 . The method of claim 51 , wherein the step of alkoxylating is carried out under alkoxylating conditions, wherein the alkoxylation conditions include the presence of a strong base. 81 . The method of claim 80 , wherein the strong base is selected from the group consisting of one or more alkali metals. 82 . The method of claim 80 , wherein the strong base is selected from the group consisting of metallic potassium, metallic sodium, sodium-potassium alloys, and a hydroxide. 83 . The method of claim 82 , wherein the hydroxide is NaOH, KOH and mixtures thereof. 84 . The method of claim 82 , wherein the strong base is a sodium-potassium alloy. 85 . The method of claim 80 , wherein the strong base is an alkoxide of a previously isolated alkoxylatable oligomer. 86 . The method of claim 80 , wherein the strong base is present in a catalytic amount. 87 . The method of claim 86 , wherein the catalytic amount is from 0.001 to 10.0 weight percent strong base based upon the weight of the total reaction mixture. 88 . The method of claim 86 , wherein the catalytic amount is from 0.01 to about 6.0 weight percent strong base based upon the weight of the total reaction mixture. 89 . The method of claim 51 , wherein the step of alkoxylating is carried out under alkoxylating conditions wherein the amount of water present is less than 20 ppm. 90 . The method of claim 89 , wherein the step of alkoxylating is carried out under alkoxylating conditions wherein the amount of water present is less than 14 ppm. 91 . The method of claim 90 ,
Antineoplastic agents · CPC title
Drugs for disorders of the respiratory system · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
for biomedical use · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.